1
|
Bérard A. Pharmacoepidemiology Research-Real-World Evidence for Decision Making. Front Pharmacol 2021; 12:723427. [PMID: 34557096 PMCID: PMC8452957 DOI: 10.3389/fphar.2021.723427] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Accepted: 08/16/2021] [Indexed: 12/27/2022] Open
Affiliation(s)
- Anick Bérard
- Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.,Faculty of Medicine, Université Claude Bernard Lyon 1, Lyon, France.,CHU Sainte-Justine, Montreal, QC, Canada
| |
Collapse
|
2
|
Finlay HJ, Jiang J, Rampulla R, Salvati ME, Qiao JX, Wang TC, Lawrence RM, Harikrishnan LS, Kamau MG, Taylor DS, Chen AYA, Yin X, Huang CS, Chang M, Chen XQ, Sleph PG, Xu C, Li J, Levesque P, Adam LP, Wexler RR. Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor. ACS Med Chem Lett 2019; 10:911-916. [PMID: 31223447 DOI: 10.1021/acsmedchemlett.9b00086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Accepted: 04/30/2019] [Indexed: 11/28/2022] Open
Abstract
Lead optimization of the diphenylpyridylethanamine (DPPE) and triphenylethanamine (TPE) series of CETP inhibitors to improve their pharmaceutical profile is described. Polar groups at the N-terminus position in the DPPE series resulted in further improvement in potency and pharmaceutical properties concomitant with retaining the safety, efficacy, and pharmacokinetic (PK) profile. A structure-activity relationship observed in the DPPE series was extended to the corresponding analogs in the more potent TPE series, and further optimization resulted in the identification of 2-amino-N-((R)-1-(3-cyclopropoxy-4-fluorophenyl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanamide (13). Compound 13 demonstrated no significant changes in either mean arterial blood pressure or heart rate in telemetry rats, had an excellent PK profile, and demonstrated robust efficacy in human CETP/apo-B-100 dual transgenic mice and in hamsters.
Collapse
|
3
|
Lama S, Souraya D, Youssef F. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. Int J Clin Pharm 2017; 39:919-926. [PMID: 28523462 DOI: 10.1007/s11096-017-0483-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Accepted: 05/08/2017] [Indexed: 10/19/2022]
Abstract
Background Current guidelines recommend a low-density lipoprotein cholesterol goal of <1.8 mmol/L (<70 mg/dL) and a non high-density lipoprotein cholesterol (non-HDL-C) goal of <2.6 mmol/L (<00 mg/dL) for coronary artery disease (CAD) patients. Objective This study aimed to describe real-life statin prescription strategies and to assess their effectiveness in terms of LDL-C and non-HDL-C goals attainment in a cohort of CAD patients. Setting Outpatient cardiology specialty clinics located in main Lebanese cities. Methods This is a retrospective crosssectional study. Eligible patients were those who had established CAD, treated with statins and having complete follow-up lipid panel at least 3 months from statin prescription. The following statin prescription strategies were considered in data analysis: prescription of different intensity statin as monotherapy, prescription of a statin in combination with: a low fat diet, another lipid-altering agent and another lipidaltering agent plus a low fat diet. Main outcome measure LDL-C goal attainment for each of the statin prescription strategy. Results Of the 423 CAD statin-treated patients, only 38.5 and 36.6% attained their recommended LDL-C and non-HDL-C goals, respectively. Using a statin in combination with ezetimibe or with another lipid-altering agent plus a low fat diet were significantly associated with LDL-C and non-HDL-C goals attainment. Conclusion Improvement of statin prescription strategies, such as using regular and scheduled dosage of high-intensity statins and combining statin therapy with ezetimibe, is therefore required when managing patients with CAD.
Collapse
Affiliation(s)
- Soubra Lama
- Department of Pharmacy Practice, Beirut Arab University, Beirut, Lebanon.
| | - Domiati Souraya
- Department of Pharmacology and Therapeutics, Beirut Arab University, Beirut, Lebanon
| | - Fattouh Youssef
- Department of Pharmacy Practice, Beirut Arab University, Beirut, Lebanon
| |
Collapse
|
4
|
Tran AT, Straand J, Dalen I, Birkeland KI, Claudi T, Cooper JG, Meyer HE, Jenum AK. Pharmacological primary and secondary cardiovascular prevention among diabetic patients in a multiethnic general practice population: still room for improvements. BMC Health Serv Res 2013; 13:182. [PMID: 23688317 PMCID: PMC3664587 DOI: 10.1186/1472-6963-13-182] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Accepted: 05/16/2013] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Ethnic minority groups have higher prevalence of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). We assessed general practitioners' (GPs') performance with respect to the pharmacological prevention of CVD in patients with T2DM from different ethnic backgrounds in Oslo. METHODS Of 1653 T2DM patients cared for by 49 GPs in 2005, 380 had a diagnosis of CVD. Ethnicity was categorized as Norwegian, South Asian and other. Risk factor levels, medication use, achievement of treatment targets (HbA1c ≤ 7.5%, systolic blood pressure (SBP) ≤ 140 mmHg, total cholesterol/HDL-cholesterol < 4) and therapeutic intensity (number of drugs targeting each risk factor) were recorded. Chi-square, Wald tests and multiple linear regression analyses were used. RESULTS Of the 1273 patients receiving primary prevention, 1.5% had their Hb1Ac, 4.8% SBP and 12.7% lipids levels above treatment thresholds without relevant prescriptions. Among patients on pharmacological therapy, 66% reached the HbA1c, 62% SBP and 62% lipid target. Proportions not achieving the HbA1c target were 26% in Norwegians, 38% in South Asians and 29% in others (p = 0.008). Proportions not achieving the SBP target were 42% in Norwegians, 22% in South Asians and 25% in others (p ≤ 0.001). Of those not achieving the HbA1c and SBP targets, 43% and 35% respectively, used only one agent. CONCLUSIONS Norwegian GPs comply reasonably well with guidelines for pharmacological prevention of CVD in T2DM patients across ethnic groups. However, lipid-lowering therapy was generally underused, and the achievement of treatment targets for HbA1c in ethnic minorities and for BP in Norwegians could be improved.
Collapse
|
5
|
Suhrcke M, Boluarte TA, Niessen L. A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries. BMC Public Health 2012; 12:2. [PMID: 22214510 PMCID: PMC3299641 DOI: 10.1186/1471-2458-12-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2011] [Accepted: 01/03/2012] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Low-and middle-income countries are facing both a mounting burden of cardiovascular disease (CVD) as well as severe resource constraints that keep them from emulating some of the extensive strategies pursued in high-income countries. There is thus an urgency to identify and implement those interventions that help reap the biggest reductions of the CVD burden, given low resource levels. What are the interventions to combat CVDs that represent good "value for money" in low-and middle-income countries? This study reviews the evidence-base on economic evaluations of interventions located in those countries. METHODS We conducted a systematic literature review of journal articles published until 2009, based on a comprehensive key-word based search in generic and specialized electronic databases, accompanied by manual searches of expert databases. The search strategy consisted of freetext and MeSH terms related to economic evaluation and cardiovascular disease. Two independent reviewers verified fulfillment of inclusion criteria and extracted study characteristics. RESULTS Thirty-three studies met the selection criteria. We find a growing research interest, in particular in most recent years, if from a very low baseline. Most interventions fall under the category primary prevention, as opposed to case management or secondary prevention. Across the spectrum of interventions, pharmaceutical strategies have been the predominant focus, and, taken at face value, these show significant positive economic evidence, specifically when compared to the counterfactual of no interventions. Only a few studies consider non-clinical interventions, at population level. Almost half of the studies have modelled the intervention effectiveness based on existing risk-factor information and effectiveness evidence from high-income countries. CONCLUSION The cost-effectiveness evidence on CVD interventions in developing countries is growing, but remains scarce, and is biased towards pharmaceutical interventions. While the burden of cardiovascular disease is growing in these countries, future research should put greater emphasis on non-clinical interventions than has hitherto been the case. Significant differences in outcome measures and methodologies prohibit a direct ranking of the interventions by their degree of cost-effectiveness. Considerable caution should be exercised when transferring effectiveness estimates from developed countries for the purpose of modelling cost-effectiveness in developing countries. New local CVD risk factor and intervention follow-up studies are needed. Some pharmaceutical strategies appear cost-effective while clarifications are needed on the diagnostic approach in single high-risk factor vs. absolute risk targeting, the role of patient compliance, and the potential public health consequences of large-scale medicalization.
Collapse
Affiliation(s)
- Marc Suhrcke
- Norwich School of Medicine, University of East Anglia, Norwich NR4 7TJ, UK
- UKCRC Centre for Diet and Activity Research (CEDAR), Robinson Way, Cambridge CB2 0SR, UK
| | - Till A Boluarte
- Department of Medicine, University of Witten/Herdecke, Faculty of Health, Alfred-Herrhausen-Str. 50, 58448 Witten, Germany
| | - Louis Niessen
- Norwich School of Medicine, University of East Anglia, Norwich NR4 7TJ, UK
- UKCRC Centre for Diet and Activity Research (CEDAR), Robinson Way, Cambridge CB2 0SR, UK
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore, MD, USA
| |
Collapse
|
6
|
Aggarwal B, Mosca L. Lifestyle and psychosocial risk factors predict non-adherence to medication. Ann Behav Med 2011; 40:228-33. [PMID: 20668975 DOI: 10.1007/s12160-010-9212-6] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Blood pressure and cholesterol reduction have proven effective to reduce cardiovascular disease (CVD) risk, yet adherence to medical therapy is suboptimal and contributing factors to non-adherence are not well-established. The purpose of this study was to determine the prevalence and predictors of non-adherence to blood pressure and cholesterol-lowering medications in individuals who participated in an NHLBI-sponsored evaluation of a hospital-based screening and outreach program for high-risk employees and the community. This was a cross-sectional study of 371 adults (mean age 60 years, 57% female, 60% non-white) who were eligible to participate if they were men >40 years, women >50 years, or had established CVD or CVD-risk equivalent. Each participant received a comprehensive standardized CVD screening evaluation; medication non-adherence was defined as missing any pills for high blood pressure or abnormal cholesterol in the past week. Associations between participant demographics, lifestyle and psychosocial risk factors, and non-adherence were assessed using logistic regression to adjust for confounders. The prevalence of taking medication for high blood pressure or abnormal cholesterol in the study population was 48% and 38%, respectively. Among those participants, 14% reported missing high blood pressure pills and 23% reported missing cholesterol pills in the past week. Significant (p<0.05) univariate predictors of non-adherence to blood pressure medication were smoking, depression, feeling sad or blue for 2 weeks or more, and eating fast food ≥2 times per week. In a multivariable regression model adjusted for confounders, participants who reported missing any blood pressure pills in the past week were 6.6 times more likely to have uncontrolled hypertension (≥140/90 mmHg) compared to those who were adherent (95% CI = 2.1-20.2). Age <65 years and eating outside the home ≥2 times per week were significantly associated with non-adherence to cholesterol medication even after adjusting for measured confounders. Non-adherence to preventive medications was associated with poor blood pressure control and several lifestyle and psychosocial risk factors for CVD. This information may be clinically useful to help identify individuals who may be non-adherent to medical therapy and at increased CVD risk.
Collapse
Affiliation(s)
- Brooke Aggarwal
- Columbia University Medical Center, 601 West 168th Street, Suite 43, New York, NY, 10032, USA
| | | |
Collapse
|
7
|
Pettersson B, Ambegaonkar B, Sazonov V, Martinell M, Stålhammar J, Wändell P. Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). BMC Public Health 2010; 10:737. [PMID: 21114824 PMCID: PMC3009647 DOI: 10.1186/1471-2458-10-737] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2010] [Accepted: 11/29/2010] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Data on the prevalence of dyslipidemia and attainment of goal/normal lipid levels in a Swedish population are scarce. The objective of this study is to estimate the prevalence of dyslipidemia and attainment of goal/normal lipid levels in patients treated with lipid modifying therapy (LMT). METHODS This longitudinal retrospective observational study covers time periods before and after treatment. Data were collected from 1994-2007 electronic patient records in public primary healthcare centers in Uppsala County, Sweden. Patients were included if they had been treated with LMT and had at least one lipid abnormality indicating dyslipidemia and if complete lipid profile data were available. Thresholds levels for lipids were defined as per Swedish guidelines. RESULTS Among 5,424 patients included, at baseline, the prevalence of dyslipidemia (≥1 lipid abnormality) was by definition 100%, while this figure was 82% at follow-up. At baseline, 60% had elevated low-density lipoprotein (LDL-C) combined with low high-density lipoprotein (HDL-C) and/or elevated triglycerides (TG s), corresponding figure at follow-up was 36%. Low HDL-C and/or elevated TGs at follow-up remained at 69% for patients with type 2 diabetes mellitus (T2DM), 50% among patients with coronary heart disease (CHD) and 66% among patients with 10 year CHD risk >20%. Of the total sample, 40% attained goal levels of LDL-C and 18% attained goal/normal levels on all three lipid parameters. CONCLUSIONS Focusing therapy on LDL-C reduction allows 40% of patients to achieve LDL-C goal and helps reducing triglyceride levels. Almost 60% of patients experience persistent HDL-C and/or triglyceride abnormality independently of LDL-C levels and could be candidates for additional treatments.
Collapse
Affiliation(s)
- Billie Pettersson
- Center for Medical Technology Assessment, Linköping University, Linköping, Sweden
- Merck Sharp & Dohme (Sweden) AB, Sollentuna, Sweden
| | | | | | - Mats Martinell
- Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
| | - Jan Stålhammar
- Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
| | - Per Wändell
- Centre for Family and Community Medicine, Karolinska Institute, Huddinge, Sweden
| |
Collapse
|